CSIMarket
 


Biogen Inc   (BIIB)
Other Ticker:  
 
 

BIIB's Revenue Growth by Quarter and Year

Biogen Inc 's Revenue results by quarter and year




BIIB Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 2,544.00 2,733.80 2,852.60
III Quarter September - 2,508.50 2,778.90 3,376.10
II Quarter June 2,456.00 2,589.10 2,775.00 3,681.60
I Quarter March 2,463.00 2,531.80 2,694.00 3,534.30
FY   4,919.00 10,173.40 10,981.70 13,444.60



BIIB Revenue second quarter 2023 Y/Y Growth Comment
Biogen Inc reported decrease in Revenue in the second quarter 2023 by -5.14% to $ 2,456.00 millions, from the same quarter in 2022.
The decrease in the second quarter 2023 Biogen Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 10.54%.

Looking into second quarter 2023 results within Biotechnology & Pharmaceuticals industry 45 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue decline of -5.14% ranks overall at the positon no. 2637 in the second quarter 2023.




BIIB Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -6.94 % -4.16 % -22.3 %
III Quarter September - -9.73 % -17.69 % -6.22 %
II Quarter June -5.14 % -6.7 % -24.63 % 1.79 %
I Quarter March -2.72 % -6.02 % -23.78 % 1.28 %
FY   - -7.36 % -18.32 % -6.49 %

Financial Statements
Biogen Inc 's second quarter 2023 Revenue $ 2,456.00 millions BIIB's Income Statement
Biogen Inc 's second quarter 2022 Revenue $ 2,589.10 millions Quarterly BIIB's Income Statement
New: More BIIB's historic Revenue Growth >>


BIIB Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 1.42 % -1.62 % -15.51 %
III Quarter September - -3.11 % 0.14 % -8.3 %
II Quarter June -0.28 % 2.26 % 3.01 % 4.17 %
I Quarter March -3.18 % -7.39 % -5.56 % -3.73 %
FY (Year on Year)   - -7.36 % -18.32 % -6.49 %




Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #46
Healthcare Sector #441
Overall #2637

Revenue Y/Y Growth Statistics
High Average Low
96.03 % 10.54 % -24.63 %
(Dec. 31, 2004)   (Jun 30 2021)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #46
Healthcare Sector #441
Overall #2637
Revenue Y/Y Growth Statistics
High Average Low
96.03 % 10.54 % -24.63 %
(Dec. 31, 2004)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Biogen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
80.67 % 3.14 % -15.51 %
(March 31, 2004)  


BIIB's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Biogen Inc reported decrease in Revenue from the previous quarter by -0.28% to $ 2,456.00 millions, from $ 2,463.00 millions achived in the previous reporting period.

Albeit periodic factors usually elevate II. Quarter 2023 performance, this simply could not be substantial to salvage BIIB's outcome, George  Wood, Healthcare sector advisor said and continued that average sequential Revenue growth is at 3.14% for Biogen Inc .

Within Biotechnology & Pharmaceuticals industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 2510.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #52
Healthcare Sector #447
Overall #2510
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #52
Healthcare Sector #447
Overall #2510
Revenue Q/Q Growth Statistics
High Average Low
80.67 % 3.14 % -15.51 %
(March 31, 2004)  


BIIB's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Biogen Inc disclosed decrease in Revenue from the first quarter by -0.28% to $ 2,456.00 millions, from $ 2,463.00 millions released in the previous reporting period.

Even seasonal factors which usually energize II. Quarter 2023 Revenue, this simply has not been sufficient to salvage BIIB's II. Quarter outcome, George  Wood, Healthcare sector advisor pointed out.

Within Biotechnology & Pharmaceuticals industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 2510.


Biogen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 9,971.50 $ 10,104.60 $ 10,173.40 $ 10,363.20 $ 10,633.60
Y / Y Revenue Growth (TTM) -6.23 % -6.61 % -7.36 % -6.64 % -9.1 %
Year on Year Revenue Growth Overall Ranking # 141 # 152 # 2214 # 2747 # 87
Seqeuential Revenue Change (TTM) -1.32 % -0.68 % -1.83 % -2.54 % -1.72 %
Seq. Revenue Growth (TTM) Overall Ranking # 125 # 2665 # 1882 # 2879 # 90




Cumulative Revenue growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Biogen Inc 's annual Revenue decline would be -6.23% year on year to $9,972 millions.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 141, from total ranking in previous quarter at 152.

Revenue TTM Q/Q Growth Statistics
High Average Low
41.42 %
9.68 %
-22.17 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 8
Overall # 141

Revenue TTM Y/Y Growth Statistics
High Average Low
41.42 %
9.68 %
-22.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 6
S&P 500 # 125
Cumulative Revenue growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Biogen Inc 's annual Revenue fall would be -6.23% year on year to $9,972 millions.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 141, from total ranking in previous quarter at 152.

Revenue TTM Q/Q Growth Statistics
High Average Low
41.42 %
9.68 %
-22.17 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 8
Overall # 141

Revenue TTM Y/Y Growth Statistics
High Average Low
41.42 %
9.68 %
-22.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 6
S&P 500 # 125




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BIIB's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for BIIB's Competitors
Revenue Growth for Biogen Inc 's Suppliers
Revenue Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Aquestive Therapeutics Inc -0.18%$ -0.181 millions
Phibro Animal Health Corporation-0.34%$ -0.340 millions
Procyon Corporation-0.59%$ -0.589 millions
Amedisys Inc-0.88%$ -0.882 millions
Baxter International Inc -1.04%$ -1.041 millions
Healthcare Services Group Inc -1.39%$ -1.395 millions
Bio rad Laboratories Inc -1.54%$ -1.536 millions
Harvard Bioscience Inc-1.83%$ -1.832 millions
Embecta Corp -1.92%$ -1.924 millions
Enhabit Inc -2.13%$ -2.127 millions
Icu Medical Inc-2.26%$ -2.260 millions
Tandem Diabetes Care Inc -2.26%$ -2.261 millions
West Pharmaceutical Services Inc -2.27%$ -2.269 millions
Coherus Biosciences inc -2.39%$ -2.386 millions
Hookipa Pharma inc -2.44%$ -2.440 millions
Biolife Solutions Inc -2.53%$ -2.529 millions
Inspiremd Inc -2.61%$ -2.613 millions
Enanta Pharmaceuticals Inc-3.01%$ -3.014 millions
National Research Corporation-3.03%$ -3.033 millions
Intellia Therapeutics Inc -3.11%$ -3.108 millions
Orgenesis Inc -3.14%$ -3.138 millions
Organogenesis Holdings Inc -3.36%$ -3.365 millions
Marker Therapeutics inc -3.52%$ -3.523 millions
Akumin Inc -3.79%$ -3.793 millions
Endo International Plc-3.91%$ -3.912 millions
Zimvie Inc -4.12%$ -4.122 millions
Integra Lifesciences Holdings Corp-4.16%$ -4.160 millions
Universal Biosensors Inc -4.18%$ -4.177 millions
Sonendo Inc -4.26%$ -4.257 millions
Avinger Inc -4.27%$ -4.268 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com